# Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid Tumors

> **NCT05730361** · PHASE1 · UNKNOWN · sponsor: **Peking University** · enrollment: 48 (estimated)

## Conditions studied

- Digestive System Malignant Solid Tumors

## Interventions

- **BIOLOGICAL:** ScTIL injection
- **BIOLOGICAL:** ScTIL injection and B lymphocytes adjuvant

## Key facts

- **NCT ID:** NCT05730361
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-02
- **Primary completion:** 2024-05
- **Final completion:** 2024-08
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2023-02-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05730361

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05730361, "Phase Ib Clinical Study on the Safety, the Tolerability, the Pharmacokinetics and the Efficacy of ScTIL Injection (Gene Modified Tumor Infiltrating Lymphocytes) Alone and in Combination With B Lymphocyte Adjuvant in the Treatment of Digestive System Malignant Solid Tumors". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT05730361. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*